CORE--CLINICAL

肯塔基州大学阿尔茨海默病研究中心（UK-ADRC）临床核心的目标是提供临床数据、研究参与者和获得研究尸检材料的方法。我们建议：（1）扩大现有的社区居住的正常老年人对照组的参与者进行尸检。我们将增加100名新的对照组，他们由于载脂蛋白-E4等位基因状态和家族史而具有发展AD的高风险，现有的374名积极随访的对照组总数为474名。这些参与者接受了广泛的认知测试，代表了研究神经病理学改变与衰老认知表现之间关系的独特资源。对照组中表现出认知变化或发生痴呆的参与者继续积极参与临床核心。(2)扩大现有的一组特征良好的痴呆症患者尸检。我们将在现有的120人的团队中招募80名新员工，使总人数达到200人。额颞叶痴呆患者。路易体痴呆、血管性痴呆和其他比AD发生率低的痴呆症将包括在本次招募中。正在进行的征聘将使200个诊所的活跃人数保持不变。进入护理机构或因其他原因无法参加诊所的先前活跃的诊所参与者将继续随访至尸检。我们计划每年从痴呆症患者中进行大约24次尸检，为研究提供材料。这份材料特别有价值，因为可以使用来自正常老年对照受试者的平行纵向和尸检数据进行比较。(3)继续为记忆障碍患者提供专家评估和诊断，并将他们的数据添加到现有的988人登记册中，这些人是合作，治疗和治疗发起的研究的潜在参与者。在过去的四年中，临床核心平均每年有249名新患者和253名返回患者进行评估。(4)评估和跟踪服务不足的农村和少数民族痴呆症患者在东肯塔基州卫星诊断和治疗诊所和Meharry卫星诊断和治疗诊所（M-SDTC）。

The objective of the University of Kentucky Alzheimer's Disease Research Center (UK-ADRC) Clinical Core is to provide clinical data, study participants and the means of obtaining autopsy materials for research. We propose the following: (1) Expand the existing group of community-dwelling normal elderly control participants followed to autopsy. We will add 100 new controls, who are at high risk of developing AD by virtue of their apolipoprotein-E4 allele status and family history, to the existing group of 374 actively followed for a total of 474. These participants undergo extensive cognitive testing and represent a unique resource for research into the relation between neuropathologic alterations and cognitive performance in aging. Participants in the control group who demonstrate cognitive change or who develop dementia continue to be active followed by the Clinical Core. (2) Expand the existing group of well-characterized individuals with dementia followed to autopsy. We will recruit 80 new individuals to the existing group of 120 for a total of 200. Patients with frontotemporal dementia. dementia with Lewy bodies, vascular dementia, and other dementing disorders less frequent than AD will be included in this recruitment. Ongoing recruitment will maintain a constant active clinic number of 200. Previously active clinic participants entering nursing facilities or otherwise unable to attend clinic will continue to be followed to autopsy. We project approximately 24 autopsies per year from the group with dementia, providing material for research. This material is particularly valuable because of the parallel longitudinal and autopsy data from the normal aged control subjects which can be used for comparison. (3) Continue to provide expert evaluation and diagnosis to individuals with memory disorders, and add their data to the existing registry of 988 individuals who are potential participants in cooperative, therapeutic and investigator-initiated research studies. In the past four years the Clinical Core has averaged 249 new and 253 return patient evaluations per year for this purpose. (4) Evaluate and follow under-served rural and minority patients with dementia in the Eastern Kentucky Satellite Diagnostic and Treatment Clinic and the Meharry Satellite Diagnostic and Treatment Clinic (M-SDTC.)